What is HC Wainwright’s Forecast for GLUE Q3 Earnings?

Posted by George Bondi on Oct 6th, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Free Report) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Monte Rosa Therapeutics in a research note issued to investors on Thursday, October 1st. HC Wainwright analyst M. Kapoor expects that the company will earn ($0.45) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Monte Rosa Therapeutics’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.81) EPS, Q1 2027 earnings at ($0.52) EPS, Q2 2027 earnings at ($0.54) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.22) EPS.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $8.97 million for the quarter, compared to the consensus estimate of $12.91 million. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%.

A number of other brokerages have also weighed in on GLUE. Weiss Ratings lowered Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Wells Fargo & Company cut their price target on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Wedbush restated an “outperform” rating and set a $27.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday, September 9th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Finally, Guggenheim reiterated a “buy” rating and issued a $28.00 price objective on shares of Monte Rosa Therapeutics in a report on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.62.

Read Our Latest Report on Monte Rosa Therapeutics

Monte Rosa Therapeutics Stock Performance

Shares of GLUE opened at $10.27 on Monday. Monte Rosa Therapeutics has a 52 week low of $7.24 and a 52 week high of $25.77. The stock has a market capitalization of $876.13 million, a price-to-earnings ratio of -5.84 and a beta of 1.37. The stock has a fifty day moving average of $14.39 and a 200-day moving average of $17.68.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Allworth Financial LP bought a new stake in shares of Monte Rosa Therapeutics in the 2nd quarter valued at about $30,000. Seven Fleet Capital Management LP bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth about $63,000. E Fund Management Co. Ltd. acquired a new position in shares of Monte Rosa Therapeutics in the second quarter worth approximately $200,000. Pallas Capital Advisors LLC acquired a new position in shares of Monte Rosa Therapeutics in the second quarter worth approximately $221,000. Finally, Wealth Effects LLC bought a new stake in Monte Rosa Therapeutics in the second quarter valued at approximately $244,000. 79.96% of the stock is owned by institutional investors.

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions.